• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Taxotere (Docetaxel)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Taxotere (Docetaxel)

  • Profile

Profile

Contact Information

Contact: Sanofi
Website: https://www.sanofi.com/

Currently Enrolling Trials

    Show More

    General Information

    Taxotere has been approved as a treatment for subjects who have locally advanced or metastatic (spreading) breast cancer, which has progressed during anthracycline-based therapy or has relapsed during anthracycline-based adjuvant therapy. Approximately two out of three breast cancer subjects treated with chemotherapy in the U.S. receive anthracyclines at some point in the treatment of their disease.

    Anthracycline-based chemotherapy is commonly used by oncologists as initial therapy for metastatic disease and as adjuvant chemotherapy administered in conjunction with surgery to prevent disease recurrence. In subjects with advanced disease, their cancer will eventually become resistant and stop responding to the treatment.

    As of June 1998, Taxotere is approved for first-line treatment of metastatic breast cancer in subjects whose disease has recurred despite adjuvant therapy.

    Mechanism of Action

    Taxotere is a chemical entity that inhibits cancer cell growth, which depends on the formation of an internal cellular skeleton made up of elements called microtubules. During the cell development cycle, microtubules first assemble and then disassemble, permitting cancer cells to divide and thus allow tumor growth. Taxotere essentially freezes the cancer cell's internal skeleton by promoting the assembly and blocking the disassembly of microtubules. This action prohibits cancer cell division, which causes cell death.

    Side Effects

    Side effects have been shown to be predictable and manageable. They include

    ·         Hair loss

    ·         Reduced white blood cell count

    ·         Skin rash

    ·         Fluid retention

    ·         Hypersensitivity

    ·         Nausea

    ·         Diarrhea

    Dosing/Administration

    Unlike other chemotherapeutic agents, Taxotere can be administered outside the hospital. The approved outpatient regimen for Taxotere is 60 to 100 mg/m2 administered intravenously for one hour every three weeks. Other currently used chemotherapy agents may require hospitalization due to much longer infusion times.

    Clinical Trial Results

    In worldwide phase 2 clinical trials, Taxotere demonstrated the highest tumor response rates ever reported for a single agent in this subject population.

    Taxotere has been studied extensively in clinical trials involving thousands of subjects worldwide, including the United States, Canada, Japan and Europe. Additional clinical trials are ongoing to investigate the potential use of Taxotere to treat other tumor types.

    Additional Information

    In the United States, breast cancer is the most common form of cancer in women. Each year 183,000 new cases are diagnosed and nearly 45,000 subjects die. Although many women are treated successfully initially, about 50 percent of breast cancer subjects will eventually relapse or recur. When this happens, the cancer often metastasizes or spreads beyond the breast to other parts of the body, such as the liver or bone. For women between the ages of 40 and 55, metastatic breast cancer is the leading cause of death.

    Approval Date: 1996-05-01
    Company Name: Rhone Poulenc Rorer
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing